Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care

被引：52

作者：

Al-Samkari, Hanny ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA

来源：

BLOOD | 2021年 / 137卷 / 07期

关键词：

ENDOTHELIAL GROWTH-FACTOR; EPISTAXIS SEVERITY SCORE; VASCULAR MALFORMATIONS; IRON-DEFICIENCY; TRANEXAMIC ACID; DOUBLE-BLIND; FACTOR-VIII; BEVACIZUMAB; THALIDOMIDE; ANEMIA;

D O I：

10.1182/blood.2020008739

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the emergence and development of antiangiogenic therapies to eliminate bleeding telangiectasias and achieve hemostasis. This progress is reflected in recent clinical recommendations published in the Second International Guidelines for the Diagnosis and Treatment of HHT, in which systemic therapies including antiangiogenics and antifibrinolytics are now recommended as standard treatment options for bleeding. This review highlights the new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and anemia in patients with HHT.

引用

页码：888 / 895

页数：8

共 77 条

[31] Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship [J].

Haas, JD ;

Brownlie, T .

JOURNAL OF NUTRITION, 2001, 131 (02) :676S-688S

[32] VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2 [J].

Han, Chul ;

Choe, Se-woon ;

Kim, Yong Hwan ;

Acharya, Abhinav P. ;

Keselowsky, Benjamin G. ;

Sorg, Brian S. ;

Lee, Young-Jae ;

Oh, S. Paul .

ANGIOGENESIS, 2014, 17 (04) :823-830

[33] EFFECT OF ESTROGEN ON NASAL RESPIRATORY MUCOSA - EXPERIMENTAL HISTOPATHOLOGICAL AND HISTOCHEMICAL STUDY [J].

HELMI, AM ;

ELGHAZZAWI, IF ;

MANDOUR, MA ;

SHEHATA, MA .

JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1975, 89 (12) :1229-1241

[34] An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia [J].

Hoag, Jeffrey B. ;

Terry, Peter ;

Mitchell, Sally ;

Reh, Douglas ;

Merlo, Christian A. .

LARYNGOSCOPE, 2010, 120 (04) :838-843

[35]

Hosman A, 2019, ANGIOGENESIS, V22, P629

[36]

Hosman AE, 2015, RHINOLOGY, V53, P340, DOI [10.4193/Rhin14.289, 10.4193/Rhino14.289]

[37] Successful Treatment of Hereditary Hemorrhagic Telangiectasia With Octreotide [J].

Houghton, Kimberly D. ;

Umar, Beena ;

Schairer, Jason .

ACG CASE REPORTS JOURNAL, 2019, 6 (06)

[38] Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study [J].

Invernizzi, Rosangela ;

Quaglia, Federica ;

Klersy, Catherine ;

Pagella, Fabio ;

Ornati, Federica ;

Chu, Francesco ;

Matti, Elina ;

Spinozzi, Giuseppe ;

Plumitallo, Sara ;

Grignani, Pierangela ;

Olivieri, Carla ;

Bastia, Aella ;

Bellistri, Francesca ;

Danesino, Cesare ;

Benazzo, Marco ;

Balduini, Carlo L. .

LANCET HAEMATOLOGY, 2015, 2 (11) :E465-E473

[39]

Iyer Vivek N, 2018, Adv Hematol, V2018, P4798425, DOI 10.1155/2018/4798425

[40] Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding [J].

Iyer, Vivek N. ;

Apala, Dinesh R. ;

Pannu, Bibek S. ;

Kotecha, Aditya ;

Brinjikji, Waleed ;

Leise, Michael D. ;

Kamath, Patrick S. ;

Misra, Sanjay ;

Begna, Kebede H. ;

Cartin-Ceba, Rodrigo ;

DuBrock, Hilary M. ;

Krowka, Michael J. ;

O'Brien, Erin K. ;

Pruthi, Rajiv K. ;

Schroeder, Darrell R. ;

Swanson, Karen L. .

MAYO CLINIC PROCEEDINGS, 2018, 93 (02) :155-166

← 1 2 3 4 5 6 7 8 →